QUALITY OF COLLECTED BIOLOGICAL SPECIMENS – THE INVISIBLE PART OF THE ERROR SOURCES IN HEMOSTASIS FOR THE CLINICIANS

The introduction of modern analyzers in the laboratories that carry out hemostasis tests has led to the devolution of the sources of error from the preanalytical phase, ensuring results with a high level of reliability. The identification of the non-compliant coagulation specimens due to events related to the biological product collection from the clinic are reported by the laboratories that make these determinations. Aim: To inform clinicians about these problems, so that through preventive actions we can ensure optimal clinical management of patients. Material and methods: Selective research were conducted in the national and international specialized literature. Inclusion criteria were studies presenting the prevalence and impact of preanalytical errors with the determination of hemostasis tests, as well as recommendations regarding the identification and rejection of the non-compliant samples. Results: In the study were introduced works that reported the sources of error which may influence the quality of the laboratory results. The errors associated with blood sampling were related to the samples with hemolyzed plasma, insufficient volume taken and the accidental presence of the clot in the erythrocyte sediment. Available literature data suggests that, out of the total of 75% of the errors identified in the laboratory, 26% can have harmful effects on patient’s care, which contribute to unnecessary investigations or to the inadequate treatment and implicitly, extension of hospitalization. Conclusions: Applying corrective measures can improve the quality indicators of the coagulation specimens and implicitly the quality of the patient's health care by informing clinicians and using educational activities.